What ARCH Venture Management, LLC reported holding on Form 13F for the quarter ended Jun 30, 2026.
CIK 1274403 · Filed Aug 14, 2026
Values are as the managers reported them, in dollars.Open the Form 13F on SEC EDGAR
| 4.5M |
| ±0% |
| $155.8M |
| 14.2% |
RAPPRapport Therapeutics, Inc. | 3.7M | ±0% | $155.4M | 14.1% |
SPTXSeaport Therapeutics, Inc. | 6.3M | New | $136.6M | 12.4% |
ERASErasca, Inc. | 7.1M | ±0% | $129.9M | 11.8% |
VIRVir Biotechnology, Inc. | 12.7M | −1.7% | $129.4M | 11.8% |
MAZEMaze Therapeutics, Inc. | 4.1M | ±0% | $123M | 11.2% |
LYELLyell Immunopharma, Inc. | 3.2M | ±0% | $45.5M | 4.1% |
GENBGenerate Biomedicines, Inc. | 1.9M | ±0% | $32.8M | 3% |
TXG10x Genomics, Inc. | 217.8K | ±0% | $8.4M | 0.8% |
BOLDBoundless Bio, Inc. | 2.7M | New | $6.7M | 0.6% |
GOSSGossamer Bio, Inc. | 8.1M | ±0% | $1.3M | 0.1% |
